A Phase 1 Study of MVB-101 Administered Intraprostatically in Patients With Localized Prostate Cancer Who Are Scheduled for Radical Prostatectomy

This Phase 1, open-label, non-randomized, multicenter study will evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of MVB-101 administered by direct intraprostatic injection in adults with previously untreated localized adenocarcinoma of the prostate who are scheduled to undergo radical prostatectomy. Participants will receive MVB-101 once weekly for 4 weeks. Part A will use an i3+3 dose-escalation design to evaluate dose levels of 1, 2, 4, and 8 mg and determine the maximum tolerated dose and recommended Phase 2 dose. Part B will use a Simon two-stage dos

Trial Details

NCT ID
NCT07944508
Phase
PHASE1
Sponsor
MultiValent Biotherapies, Inc.
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • MVB-101
Locations (sample)
  • Homewood, Alabama, United States|33.47177,-86.80082
  • San Antonio, Texas, United States|29.42412,-98.49363

Key Eligibility Criteria

  • Signed informed consent form.
  • Understands the obligation and is capable of attending all follow-up visits.
  • Documented, previously untreated, localized adenocarcinoma of the prostate confirmed by multiparametric MRI and prostate biopsy within 3 months bef…
  • Scheduled for radical prostatectomy approximately 12 weeks after the first dose of MVB-101.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →